Eva Liang, MD
Ophthalmology · Las Vegas, NVNPI 1619957081
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $387,877 of the $495,901 with a category attached, or 78.2%. 28 manufacturers reported payments, led by Beaver-visitec International, Inc. at 45.7% of the total. 2025 is the largest year on record at $192,323, 2.7 times the $70,813 reported in 2019. Among ophthalmology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 533 payments — averaging $930.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beaver-visitec International, Inc.$227K
- Johnson & Johnson Surgical Vision, Inc.$82K
- Bausch & Lomb Americas Inc.$44K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$43K
- Glaukos Corporation$25K
- Sun Pharmaceutical Industries Inc.$24K
- plus $53K from 22 others
Across 603 payments — averaging $3080.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$591K
- Alcon Research LLC$456K
- Rxsight Inc$308K
- Bausch & Lomb Americas Inc.$148K
- Bausch Health US, LLC$102K
- Beaver-visitec International, Inc.$94K
- plus $158K from 5 others
What the payments were for
- Consulting fees$387,87778%
- Speaking & faculty fees$60,50612%
- Travel & lodging$18,5184%
- Food & beverage$21,0604%
- Education$2600%
- Gifts$2050%
- Other$7,4752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beaver-visitec International, Inc. | 3 | $226,605 |
| Johnson & Johnson Surgical Vision, Inc. | 62 | $81,507 |
| Bausch & Lomb Americas Inc. | 46 | $43,557 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 97 | $43,025 |
| Glaukos Corporation | 52 | $24,737 |
| Sun Pharmaceutical Industries Inc. | 33 | $23,664 |
| AbbVie(2 entities) | 77 | $17,534 |
| Alcon | 57 | $13,287 |
| Ivantis, Inc | 25 | $9,048 |
| Rxsight Inc | 17 | $4,567 |
| Oyster Point Pharma, Inc. | 11 | $2,477 |
| Eyevance Pharmaceuticals LLC | 8 | $1,528 |
| Lensar, Inc. | 1 | $1,500 |
| Kala Pharmaceuticals, Inc. | 9 | $1,123 |
| Tarsus Pharmaceuticals, Inc. | 8 | $345 |
| Amgen(2 entities) | 3 | $264 |
| Rayner Intraocular Lenses Limited | 2 | $243 |
| Sight Sciences, Inc. | 4 | $242 |
| Carl Zeiss Meditec, Inc. | 4 | $221 |
| Kestra Medical Technology Services, Inc. | 1 | $158 |
| Dompe US, Inc. | 4 | $96 |
| Novartis | 2 | $42 |
| Carl Zeiss Meditec USA, Inc. | 2 | $39 |
| Harrow Eye, LLC | 1 | $31 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $14 |
| Medline Industries LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$36,217
- Crystalens Accommodating IOL (AT-52AO)$26,128
- Trulign IOL$26,128
- Akreos AO IOL$26,128
- STELLARIS ELITE$21,853
- ENVISTA$19,981
- TRULIGN TORIC$19,448
- CRYSTALENS$19,448
- CEQUA$16,727
- Hydrus Microstent$16,269
- OPHTHALMIC INSTRUMENTS$16,230
- STELLARIS$16,057
- XEN$15,732
- Whitestar Signature Pro$12,710
- VERITAS Vision System$12,440
- enVista Aspire IOL$11,881
- TENEO$11,774
- Whitestar Signature$9,125
- STELLARIS PC$8,432
- AKREOS AO$8,432
How this compares
$495,901 in reported general payments places this provider in the 95th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $342,153 |
| RestasisCyclosporine | 48 | $50,286 |
| LumiganBimatoprost | 47 | $28,629 |
| XiidraLifitegrast | 18 | $24,863 |
| BotoxOnabotulinumtoxina | 17 | $10,999 |
| Prednisolone Acetate | 174 | $9,845 |
| VyzultaLatanoprostene Bunod | 25 | $9,333 |
| TyrvayaVarenicline Tartrate | 11 | $7,165 |
| MoxifloxacinMoxifloxacin Hcl | 60 | $2,698 |
| Ketorolac Tromethamine | 47 | $2,179 |
| Gatifloxacin | 46 | $2,117 |
| ValacyclovirValacyclovir Hcl | 20 | $1,894 |
| Timolol Maleate | 180 | $1,323 |
| Latanoprost | 133 | $1,050 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 70 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $96 | $342,15312 claims |
| AbbVieRestasis, Lumigan, Botox | $17,534 | $89,914112 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $43,557 | $34,19643 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $2,477 | $7,16511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Las Vegas
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
- Surjeet SinghLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.